Objective: To identify predictors of sick leave and improved worker productivity in early RA patients treated for 52 weeks with intensive combination strategies including prednisolone. Methods: Patients with early RA were included in the COmbinatietherapie Bij Reumatoïde Artritis (COBRA)-light trial and followed for 52 weeks. As COBRAlight strategy proved to be non-inferior to COBRA strategy on several clinical outcomes, all patients were pooled for this study. Predictors for sick leave and improved worker productivity were assessed through a 3-months' time-lag multivariable logistic generalized estimating equations (GEE) model. In other words, the presence or level of a possible predictor was related to sick leave in the following three months.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic disease with disease symptoms such as fatigue, morning stiffness, pain and inflammation in joints. Patients experience several problems in daily functioning, such as problems with cooking, clothing and performing their job. [1] Without effective treatment, 50% of patients stop working within a decade after diagnosis. [2] In the past two decades, treatment of RA has strongly improved due to the introduction of highly effective biological drugs, [3] [4] [5] [6] as well as more effective early application of existing disease modifying antirheumatic drugs (DMARDs) including glucocorticoids in combination strategies. [6] [7] [8] [9] [10] One of these effective combination strategies for the treatment of RA is the COBRA strategy (COmbinatietherapie Bij Reumatoïde Artritis), which is a combination of methotrexate (7.5 mg/week), sulfasalazine (2 gr/day) and prednisolone (60 mg/day, tapered to 7.5 mg in 7 weeks), [11] and the non-inferior COBRA-light strategy, comprising methotrexate (25 mg/week) and prednisolone (30 mg/day, tapered to 7.5 mg in 9 weeks). [12, 13] Despite strongly reduced levels of disease activity with biological DMARD treatment, many patients report being on sick leave for extended periods, and work disability is still a major problem. [14] In comparison with studies on biological drugs, there are relatively few studies which measured the effect of conventional DMARD therapy on sick leave in RA patients. [15] [16] [17] These studies mainly show a decrease of days on sick leave due to treatment, but also an increase in number of patients without a paid job, patients with a disability pension as well as on retirement. Despite the follow-up period of these studies with three to six monthly visits, no longitudinal analyses were performed. Longitudinal analyses can take all information on all visits into account, in contrast to the analysis of change over only two time points. Longitudinal analysis, such as generalized estimated equations analyses (GEE), corrects for dependent observations by modelling correlations within persons, and is suitable for repeated measurement analyses. [18, 19] Therefore, we applied longitudinal analyses to build a prediction model for sustained sick leave and higher worker productivity during one year of intensive combination treatment with prednisolone.
PATIENTS AND METHODS

Study population
This study presents the data of patients at work during the first 52 weeks of the COBRA-light trial. The in-and exclusion criteria, randomisation process and study design of this trial have been described earlier. [12] In short, 164 Dutch patients with early RA, according to the American College of Rheumatology (ACR) criteria 1989, were included from March 2008 to March 2011 after obtaining written informed consent. Patients were randomised to either COBRA or COBRA-light strategy to determine non-inferiority of COBRA-light therapy. The protocol followed a treat-to-target regimen aiming at minimal clinical disease (defined as 44 joint count disease activity score (DAS44) of 1.6 or lower). Follow-up period of this trial was two years. Patients had not been previously treated with glucocorticoids or DMARDs other than antimalarial medication. When patients did not reach minimal disease activity, etanercept was started after 26 or 39 weeks of follow-up.
Immediately after randomisation, two patients withdrew their consent. As they did not receive any medication dose, these patients were not included in the intention-to-treat analyses. In the 52 weeks of follow-up, 7 patients dropped out: three in the COBRA group and four in the COBRA-light group. Twice, the reason was poor compliance to the treatment schedule. Other reasons occurring once were intolerance to medication, myocardial infarction, bilateral pulmonary embolism, manic episode and the desire to become pregnant. Finally, 78 patients in the COBRA group and 77 patients in the COBRA-light group completed the 52 weeks of follow-up.
This study was a multicentre, randomised, open label trial (www.controlled-trials.com; ISRCTN55552928). The protocol was approved by the Medical Ethics Committees of the three participating centres: VU University Medical Center, Reade and Westfries Gasthuis. The study was performed within the standards of the Declaration of Helsinki/Good Clinical Practice.
Measurements
Trial patients were seen by a rheumatologist and a specialised nurse at baseline and every three months of follow-up. Clinical and work related characteristics were obtained by medical examination and questionnaires at each visit.
All collected variables were classified in three major groups for analyses: personal variables, disease variables and work variables.
Personal variables
These comprised age, sex, ethnicity and education level. Ethnicity was divided into a Dutch origin (no parents born outside the Netherlands) and non-Dutch origin (at least one parent born outside the Netherlands). Education was categorized based on the highest attained level and calculated in years into low (<12 years: primary school, lower and intermediate secondary education), intermediate (12 -16 years: high secondary education) and high (≥17 years: higher vocational education or university).
Disease variables
These comprised time independent and time dependent variables. Time independent (baseline) variables were rheumatoid factor (RF), anti-citrullinated peptide (anti-CCP), disease duration, treatment arm, and presence of joint damage on radiographs of hands and feet (Sharp/Van der Heijde (SHS) joint damage score ≥ 1). The disease duration was defined as the time between onset of symptoms until trial start. Time dependent variables were clinical characteristics as well as self-reported health, assessed at every visit. Visual analogue scales (VAS) assessed pain, general well-being and disease activity: range from 0 (no pain, no activity, good well-being) to 100 (very high pain, bad well-being, very active disease). [20] The Health Assessment Questionnaire (HAQ) assessed functional ability. The HAQ score consists of 20 items and ranges from no disability (score 0) to high disability (score 3). [21] Treating physicians gave an estimation of the severity of the disease activity by VAS. Presence of morning stiffness (yes/no) and its duration were measured in hours. Questions on general fatigue, depressive symptoms and sleeping problems during the last week were answered with yes/no (e.g. have you experienced any depressive symptoms in the past week?)
Work variables
Sick leave in the Netherlands is defined as absence from work and work activities due to health problems. An employer in the Netherlands is obligated to pay full salaries during the first 12 months, and 70% during the second 12 months.
In our study, sick leave in the past three months (13 weeks) was measured at every visit, and collected through (cost) diaries. Patients reported costs made related to their disease (medication, hospital visits etc.), whether they had paid work (yes/no), and if so, how many days and hours per week they worked. Secondly, patients with a job were asked whether they were on sick leave (yes/ no), and absence in number of days and hours per week. A VAS scale measured efficiency of work performance (worker productivity): range from 1 (not or hardly capable to work) to 10 (just as efficient as without disease). Employment status at baseline was classified as having no job, being retired, partly work disabled, working < 20 hours a week and working ≥ 20 hours a week. A second classification was made into blue (manual labour) and white (office labour) collar jobs.
Missing values on sick leave (yes/no), work situation (no work, retired, partly work disabled, <50% at work or ≥50% at work) and having a job (yes/ no) were imputed if an outcome was missing at one visit. Five percent (n=40) of the total number of visits (n=810) had missing information on these questions. The missing outcome (yes/no) was imputed if the outcome was the same in the visit preceding the missing visit and the upcoming visit or if the outcome of the two preceding or upcoming visits were the same. For example, if being on sick leave (yes/no) was missing at week 39 and the outcome was 'no' at week 26 and week 52, the missing value at week 39 was imputed as 'no' . Also, information on having a job at baseline was altered if patients did not fill out an answer on that particular question, but did provide information on work hours, type of job etc.
No information was collected during the trial on the status of paid job, disability pension and retirement. Therefore, only information on the percentages of patients with a paid job throughout the study can be provided.
Statistical analysis
In the COBRA-light trial, COBRA-light proved to be non-inferior to COBRA on several clinical outcomes. Therefore, data of the two treatment arms were pooled. Two prediction models were built: multivariable logistic generalized estimating equations (GEE) with an exchangeable correlation structure assessed potential predictors for sick leave (prediction model 1) and improved worker productivity (prediction model 2). A 3-month time-lag model related the result of a possible predictor to being on sick leave (yes/no) or improved worker productivity (by VAS) in the following three months. Sick leave (yes/ no) was defined as the occurrence of at least 1 day of absence from work due to illness (absenteeism) in the preceding 3 months. Improvement in worker productivity was defined as an improvement on the question: 'How efficient were you in performing your work in the past three months?' Answers were provided through a VAS (0-10) question, whereas a 0 is defined as not efficient at all and a 10 as highly efficient.
When the relationship between possible predictors and the outcome were not linear, these predictors were dichotomised based on the median or clinical cut-off values. Swollen joint count was categorised into tertiles: no swollen joints, 1-2 swollen joints and ≥3 swollen joints. Tender joint count was also divided into tertiles: no tender joints, 1-5 tender joints and ≥6 tender joints.
As the DAS44 score was highly collinear with its separate components, these were assessed separately. So analyses were performed with only the DAS components, as well as without the components, including only the DAS scores (both DAS44 as well as DAS28). Data are presented as mean values and standard deviation (SD) or as median and interquartile range (IQR) in case of skewed distribution.
The following steps were performed to identify possible predictors. In the first step all variables were analysed separately in univariable logistic GEE analyses to assess the individual associations with sick leave or improved worker productivity. All variables with a p-value of 0.20 were selected for further analyses. In the second step, separate multivariable GEE models were built for disease, personal and work related variables. The cut-off was set at a p-value of 0.10 or less. In the final step, all three multivariable models were combined to study the combined impact of disease, personal and work related variables on sick leave or improved worker productivity. In the final model, all variables with a p-value of 0.05 or less were selected. All analyses were performed on all patients with a paid job at baseline using backward selection procedure, and run on IBM SPSS statistics V.20.
RESULTS
The majority of trial patients were female (110/162, 68%), mean age was 52 (SD 13) years, and the median disease duration was 16 weeks (IQR 9-30; Table 1 ). During the trial VAS global health improved from 59 (SD 24) mm at baseline to 26 (SD 26) mm at 1 year.
At baseline, 97 persons had a paid job, 59 patients did not have a job and 6 patients had missing information on work ( Table 2 ). Employed patients were younger compared to the unemployed patients (47 (SD 11) and 60 (SD 12) years, respectively). They were also more higher educated, and were slightly more randomized to the COBRA-light strategy. The majority of the employed patients performed white collar jobs (57%), and worked ≥20 hours a week (75%). Of the unemployed patients 26 (44%) were retired, 4 (7%) had no work/were searching for work, and 10 patients (17%) were fulltime housekeeper.
During the trial, 13 patients stopped working (8%), and 6 (4%) patients started working. The mean work days according contract did not change over time. Mean work hours fluctuated a little, but were similar at baseline and end.
Percentage of patients in sick leave decreased per time moment, and the actual days and hours decreased to a median of 0 days and hours. The worker productivity at work increased with 0.2 points on the VAS scale. Patients without a paid job or with missing data about a paid job at baseline, were excluded from further analyses. Table 3 presents all univariable as well as multivariable GEE analyses for personal, disease and work related variables. For the personal variables, higher levels of education were significantly associated with lower prevalence of sick leave. When all personal variables were combined, only male gender was a predictor for sick leave (OR 0.48, 95% CI 0.23 -1.0). Gender was highly associated with high levels of education (70% of women versus 30% of men, respectively), therefore the weaker predictor (education) was not included in the final model. The impact of disease variables (including components of the DAS, but not the DAS score) on sick leave was stronger as expressed by higher odds ratios. Most variables showed univariable relations in the expected direction (Table 3 ). In the multivariable analysis, higher scores on patient global health assessment, 10 (17) 6 patients had missing information on work longer symptom duration at baseline, and the presence of fatigue remained as independent predictors. Four work variables were associated with sick leave in univariable analysis (Table 3 ). In the multivariable model, only sick leave in the past three months remained. When excluding this variable, actual days and hours as well as improved worker productivity in the past three months remained.
Prediction model 1: Sick leave
The final prediction model, combining all potential personal, disease and work variables, only contained sick leave in the past three months. When this strongly predictive variable was excluded, patient global health assessment and actual hours on sick leave became predictors (Table 4 ). All above mentioned analyses were repeated with the DAS scores, excluding all components of the DAS: results were similar (data not shown).
Prediction model 2: Efficiency at work (worker productivity)
All analyses were repeated using worker productivity at work three months later as outcome. Results are also presented in Table 3 . In the univariable analyses, the impact of demographic, disease and work variables on productivity resembled the associations as found for sick leave. For the disease variables, remarkably, being anti-CCP positive at baseline resulted in higher worker productivity at work scores.
The final prediction model combining all potential personal, disease and work variables, contained a SHS score of 1 or more, patient global health assessment, actual hours on sick leave, and higher worker productivity scores in the past three months (Table 4 ). All above mentioned analyses were repeated with the DAS scores, excluding all components of the DAS: results were similar (data not shown). 
DISCUSSION
No objective disease measure were included in both prediction models: sick leave and improved worker productivity could both be predicted by patient global assessment as well as actual hours on sick leave. Sick leave in the past three months was the strongest predictor for sick leave in the upcoming months. And a SHS score of 1 or more as well as higher worker productivity scores in the past three months also predicted improved worker productivity three months later. It seems that the overall models are a result of different variables working together. However, the almost complete absence of the so-called "objective" measures of disease activity (such as ESR) in the prediction model of sick leave, contrasting with patient global assessment is notable; in our view these findings confirm the multifactorial etiology of sick leave in RA. Of course, the results must be interpreted in the light of the setting where all patients had active RA in the beginning of the trial, and most patients responded very well to treatment, most likely limiting the amount of variability 'available' to associate with sick leave. However, a SHS score of 1 or more (and thus more radiographic erosions) is associated with improved worker productivity. This is difficult to explain as more erosions in hands and feet is associated with poor functioning and one would expect less worker productivity. This effect might be a result of the very little radiological damage present in this study as well as a result of the chosen cut-of point as used for these analyses.
The percentage of patients losing their job was nearly two times higher in the original COBRA trial compared to our study. In the original COBRA study, [11] in which 154 patients were treated with either COBRA strategy or sulfasalazine monotherapy, the percentage of patients with a paid job had decreased with 13%: from 65 (42%) patients at baseline to 44 (29%) at week 56. [16] . In our study, 97 of the 162 included patients (60%) had a paid job at baseline. This number decreased by 14% to 83 (51%) at week 52. The patients from both trials were comparable on demographic characteristics as well as on functional ability. However, in the COBRA-light trial a more tight treat-to-target strategy was proposed for the full year, (although not always properly followed by the physicians), [13] compared to mandatory tapering in the second half year in the original COBRA trial. This led to low DAS44 scores during the largest part of the current trial. As patients had lower DAS44 scores, they might have also experienced a higher patient global assessment and less tender and swollen joints, making it easier to work.
To our knowledge, this study is one of the first to assess personal, disease and work variables associated with sick leave in a longitudinal three months' time-lag model. Therefore, comparison with other studies is limited. Two studies also created prediction models on work outcome: one for work disability, [22] and one for sick leave as well as presenteeism (loss of productivity at work). [23] In the study on work disability, DMARD-naïve patients with recent onset RA were treated with a combination of DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) with prednisolone or a single DMARD with or without prednisolone. Work disability (in this study defined as a combination of sick leave and disability pension) was assessed over a 5 year period and predicted by higher age, low education level, high HAQ score category, high patient global assessment category, and high physician disease assessment category. An explanation for the differences in outcome compared to our study, is the fact that we used a different outcome (sick leave), as sick leave on its own is a known predictor for work disability. [24] Secondly, we also included work variables and thirdly, the statistical methodology differed as we performed a longitudinal analysis.
The second study is similar to our study as it also performed a longitudinal prediction model with a time lag GEE. [23] This study was part of the Rotterdam Early Arthritis Cohort (REACH). Sick leave was predicted by frequent manual handling of materials, high pain levels and poor physical functioning. In the REACH cohort only 23% were diagnosed with RA. The non-RA population consisted of patients with arthritis but not RA and patients with inflammatory joint complaints but no clinical synovitis. This is a large difference in comparison to our population. Secondly, all patients in the COBRA-light trial received conventional DMARD treatment compared to only 40% of the patients receiving DMARDs in the REACH study. And finally, we analysed the data with a 3 months' time lag compared to 6 months' time lag in the REACH study, potentially increasing recall bias.
A major strength of our study is the three months' time-lag. This allows us to be able to predict on outcome every three months later. Therefore, therapy adjustments can be more strict as a shorter time period to assess possible risk for sick leave is used. But, this study also has its limitations. We did not collect data on the trajectory of work disablement in our patients. However, we do not think this had a major impact on our data as in the Netherlands, when an employee is not able to work in fulltime duty (i.e. 8 hours a day) due to sickness, the employee will receive continued pay from the employer for a maximum of two years.
[25] Therefore, a Dutch resident will receive disability pension after two years of sick leave. Secondly, the number of patients with a paid job was mainly based on a question at baseline if patients had a paid job and on information in the cost diaries. Therefore, selection and recall bias could have occurred, as filling out a diary is a skilled activity to perform, and demanding, resulting in an possible underestimation of the actual patients with a paid job. [26] Thirdly, sick leave, as well as several possible predictors, was dichotomized. This may lead to loss of precision, but was necessary in view of distribution of the data: e.g., many patients reported having 0 days and hours on sick leave. A fourth limitation is the limited information on work related characteristics that was collected. More is becoming clear on the fact that contextual factors (e.g., job control, support from colleagues and managers) might explain the relationship with sick leave, more than disease variables. [27, 28] And finally, this study searched for predictors of sick leave in a small population of RA patients enrolled in a clinical trial of intensive active treatment. It is possible that the sample size was too small to detect other significant predictors of sick leave.
CONCLUSION
Sick leave, as well as improved worker productivity, were both mainly predicted by non-disease specific variables. Both outcomes can be predicted on a three months basis, using the outcome over the past three months for the next three months. By applying this model in daily practice, decisions for therapy change could be based not solely on disease activity, but could also take into account a possible high risk for sick leave in the upcoming three months.
